Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amnion mesenchymal cells
- Development stage
- Unknown
- Lead developer
- CTEX
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Amnion mesenchymal cells are an allogeneic **cell therapy** composed of mesenchymal stem cells isolated from human amnion tissue. The product described in clinical development is **AM01**, developed by **CTEX Corporation**, and is reported as the first manufactured clinical trial product of amnion-derived mesenchymal stem cells. These cells are intended for immune- and inflammation-related diseases and exert therapeutic activity through **immunomodulation**, including secretion of anti-inflammatory mediators such as **interleukin-10** and **prostaglandin E2**, which suppress pathogenic immune responses and dampen inflammatory cytokine networks. The program has been studied in physician-led clinical trials for **acute graft-versus-host disease** and **Crohn's disease**. The cells are characterized by non-invasive sourcing from placental amnion tissue, high proliferative capacity, and expression of canonical mesenchymal markers including **CD105**, **CD73**, and **CD90**.
- Other names
- amnion-derived mesenchymal stem cellsAMSCshuman amnion mesenchymal stem cells
Beyond the preview
Go deeper on amnion mesenchymal cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amnion mesenchymal cells.